Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin R Flaherty

Showing results (131-140 of 204) with videos related to

Pageof 21
Sort By:
American Journal of Respiratory and Critical Care Medicine|December 22, 2007
An essential role for fibronectin extra type III domain A in pulmonary fibrosisAndrés F Muro, Federico A Moretti, Bethany B Moore, et al.
The New England Journal of Medicine|October 14, 2011
Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosisLuca Richeldi, Ulrich Costabel, Moises Selman, et al.
Chest|October 22, 2023
Associations of Plasma Omega-3 Fatty Acids With Progression and Survival in Pulmonary FibrosisJohn S Kim, Shwu-Fan Ma, Jennie Z Ma, et al.
Lung|January 23, 2022
Association of Circulating Proteins with Death or Lung Transplant in Patients with Idiopathic Pulmonary Fibrosis in the IPF-PRO Registry CohortJamie L Todd, Megan L Neely, Robert Overton, et al.
Lung|February 15, 2022
Correction to: Association of Circulating Proteins with Death or Lung Transplant in Patients with Idiopathic Pulmonary Fibrosis in the IPF-PRO Registry CohortJamie L Todd, Megan L Neely, Robert Overton, et al.
Annals of the American Thoracic Society|October 22, 2021
A Phase-2 Exploratory Randomized Controlled Trial of INOpulse in Patients with Fibrotic Interstitial Lung Disease Requiring OxygenChristopher S King, Kevin R Flaherty, Marilyn K Glassberg, et al.
American Journal of Respiratory and Critical Care Medicine|July 17, 2004
Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?Kevin R Flaherty, Talmadge E King, Ganesh Raghu, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 24, 2022
Nintedanib in Patients With Autoimmune Disease-Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD TrialEric L Matteson, Clive Kelly, Jörg H W Distler, et al.
Respiratory Medicine|September 27, 2017
Possible UIP pattern on high-resolution computed tomography is associated with better survival than definite UIP in IPF patientsMargaret L Salisbury, Leslie B Tolle, Meng Xia, et al.
The Lancet. Respiratory Medicine|October 3, 2019
Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trialLuca Richeldi, Evans R Fernández Pérez, Ulrich Costabel, et al.
Pageof 21

Showing results (131-140 of 204) with videos related to

Sort By:
Pageof 21
American Journal of Respiratory and Critical Care Medicine|December 22, 2007
An essential role for fibronectin extra type III domain A in pulmonary fibrosisAndrés F Muro, Federico A Moretti, Bethany B Moore, et al.
The New England Journal of Medicine|October 14, 2011
Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosisLuca Richeldi, Ulrich Costabel, Moises Selman, et al.
Chest|October 22, 2023
Associations of Plasma Omega-3 Fatty Acids With Progression and Survival in Pulmonary FibrosisJohn S Kim, Shwu-Fan Ma, Jennie Z Ma, et al.
Lung|January 23, 2022
Association of Circulating Proteins with Death or Lung Transplant in Patients with Idiopathic Pulmonary Fibrosis in the IPF-PRO Registry CohortJamie L Todd, Megan L Neely, Robert Overton, et al.
Lung|February 15, 2022
Correction to: Association of Circulating Proteins with Death or Lung Transplant in Patients with Idiopathic Pulmonary Fibrosis in the IPF-PRO Registry CohortJamie L Todd, Megan L Neely, Robert Overton, et al.
Annals of the American Thoracic Society|October 22, 2021
A Phase-2 Exploratory Randomized Controlled Trial of INOpulse in Patients with Fibrotic Interstitial Lung Disease Requiring OxygenChristopher S King, Kevin R Flaherty, Marilyn K Glassberg, et al.
American Journal of Respiratory and Critical Care Medicine|July 17, 2004
Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?Kevin R Flaherty, Talmadge E King, Ganesh Raghu, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 24, 2022
Nintedanib in Patients With Autoimmune Disease-Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD TrialEric L Matteson, Clive Kelly, Jörg H W Distler, et al.
Respiratory Medicine|September 27, 2017
Possible UIP pattern on high-resolution computed tomography is associated with better survival than definite UIP in IPF patientsMargaret L Salisbury, Leslie B Tolle, Meng Xia, et al.
The Lancet. Respiratory Medicine|October 3, 2019
Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trialLuca Richeldi, Evans R Fernández Pérez, Ulrich Costabel, et al.
Pageof 21